Tau Post-Translational Modifications in 4R-Tauopathies

Tau Post-Translational Modifications in 4R-Tauopathies

Overview

Tau protein undergoes numerous post-translational modifications (PTMs) that critically regulate its normal function and pathological aggregation. In 4R-tauopathies—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17—specific PTM patterns contribute to the unique disease phenotypes and filament structures observed in each condition. Understanding these modifications provides insight into disease mechanisms and potential therapeutic targets. PMID: 41884598

Pathway / Mechanism Diagram

Tau Phosphorylation

Hyperphosphorylation in 4R-Tauopathies

Tau Post-Translational Modifications in 4R-Tauopathies

Overview

Tau protein undergoes numerous post-translational modifications (PTMs) that critically regulate its normal function and pathological aggregation. In 4R-tauopathies—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17—specific PTM patterns contribute to the unique disease phenotypes and filament structures observed in each condition. Understanding these modifications provides insight into disease mechanisms and potential therapeutic targets. PMID: 41884598

Pathway / Mechanism Diagram

Tau Phosphorylation

Hyperphosphorylation in 4R-Tauopathies

Tau is a microtubule-associated protein that normally binds to and stabilizes microtubules. Pathological hyperphosphorylation reduces tau's microtubule binding affinity, leading to microtubule destabilization and free tau that can aggregate into filaments. PMID: 41544664

Key Phosphorylation Sites

| Site | PSP | CBD | AGD | GGT | FTDP-17 |
|------|-----|-----|-----|-----|---------|
| Ser202 | +++ | +++ | ++ | + | +++ |
| Thr205 | +++ | +++ | ++ | + | ++ |
| Ser396 | ++ | +++ | +++ | ++ | ++ |
| Ser404 | +++ | +++ | +++ | ++ | +++ |
| Ser262 | + | ++ | + | - | + |
| Thr231 | +++ | ++ | +++ | ++ | ++ |

Key Findings:

• PSP: Prominent phosphorylation at Ser202 and Thr205 in the brainstem and basal ganglia. The "pSer202/pThr205" epitope is a hallmark of PSP tau pathology and used in diagnostic immunohistochemistry.
• CBD: Higher levels of phosphorylation at Ser396 and Ser404 compared to PSP. Phosphorylation at Ser262/Ser356 (PHF-6 domain) is particularly prominent.
• AGD: Characterized by extensive phosphorylation at Thr231 and Ser396, forming the AT180 epitope. Argyrophilic grains show distinctive phosphorylation patterns.
• GGT: Phosphorylation patterns similar to PSP but with notable involvement of the 4R isoform specific sites. 4R-tau shows higher affinity for microtubules when phosphorylated at certain sites.
• FTDP-17: Mutations affect phosphorylation kinetics. The R406W mutation reduces phosphorylation while P301L enhances aggregation propensity.

Kinases Involved

Multiple kinases contribute to tau hyperphosphorylation in 4R-tauopathies:

• GSK-3β: Primarily responsible for phosphorylation at multiple sites including Ser396/Ser404. Active in PSP and CBD brain tissue.
• CDK5: Phosphorylates tau at Ser202, Thr205, and Ser396. Dysregulated in both PSP and CBD.
• DYRK1A: Phosphorylates tau at Thr212 and Ser214, promoting aggregation. Elevated in PSP brainstem nuclei.
• PKA: Phosphorylates tau at Ser409 and Ser416, with relevance to cAMP signaling dysregulation.

Phosphatase Dysfunction

Reduced activity of protein phosphatases PP2A and PP1 contributes to hyperphosphorylation. PP2A accounts for ~70% of tau phosphatase activity in the brain, and its activity is reduced in PSP and CBD.

Tau Acetylation

Role in Aggregation

Acetylation at lysine residues promotes tau aggregation by:

Disease-Specific Patterns

• PSP: Elevated acetylation at Lys280 (acK280) in tau filaments. This modification stabilizes the pathological conformations.
• CBD: Acetylation patterns differ from PSP, with more prominent acetylation at Lys374 and Lys395.
• AGD: Moderate acetylation levels, often co-localizing with phosphorylated tau in argyrophilic grains.
• FTDP-17: Certain mutations (e.g., P301L) show increased susceptibility to acetylation-mediated aggregation.

Therapeutic Implications

HDAC6 (histone deacetylase 6) inhibitors are being explored to reduce tau acetylation and promote microtubule function. HDAC6 is elevated in PSP and CBD, making this a promising target.

Tau Ubiquitination

Ubiquitin Systems

Tau is ubiquitinated for degradation via both proteasomal and lysosomal pathways. Different ubiquitin linkage types determine the fate of tau:

• K48 linkages: Target tau for proteasomal degradation
• K63 linkages: Target tau for autophagic degradation
• K27 linkages: Found in NFT, may represent failed degradation

Disease-Specific Findings

• PSP: Prominent K63-linked ubiquitination in tau aggregates. Impaired autophagic flux contributes to accumulation.
• CBD: Both K48 and K63 ubiquitination patterns observed, suggesting both proteasomal and autophagic pathways are affected.
• AGD: Characteristic 4R tau with distinctive ubiquitination patterns in argyrophilic grains.
• GGT: Ubiquitination primarily in globular glial inclusions.
• FTDP-17: Variable ubiquitination depending on mutation.

Tau Truncation

Caspase-Mediated Cleavage

Tau is cleaved by several caspases, generating truncation products that are more aggregation-prone:

• Caspase-3: Generates tau truncation at Asp421 (Δtau421), highly aggregation-prone
• Caspase-6: Truncation at Asp523
• Caspase-2: Truncation at Asp314

Distribution in 4R-Tauopathies

• PSP: Δtau421 prominent in subcortical regions, particularly brainstem
• CBD: Higher levels of caspase-cleaved tau in cortical regions
• AGD: Moderate truncation in argyrophilic grains
• GGT: Truncation patterns associated with glial tau pathology

O-GlcNAcylation

Protective Modification

O-GlcNAcylation is a nutrient-responsive modification that competes with phosphorylation at nearby sites. It can:

• Reduce tau phosphorylation
• Inhibit aggregation
• Promote tau clearance

Therapeutic Potential

• Reduced in PSP/CBD: O-GlcNAc transferase (OGT) activity is decreased, contributing to hyperphosphorylation
• Therapeutic target: Small molecule OGT activators are under investigation

SUMOylation

Regulation of Aggregation

SUMOylation can:

• Modulate tau phosphorylation status
• Affect protein-protein interactions
• Influence degradation pathways

Disease Relevance

• PSP: Elevated SUMOylation in tau-positive neurons
• CBD: Different SUMOylation patterns compared to PSP
• AGD: Present but less prominent than in PSP/CBD

Cross-Disease Comparison Summary

| PTM | PSP | CBD | AGD | GGT | FTDP-17 |
|-----|-----|-----|-----|-----|---------|
| Phosphorylation (Ser202/Thr205) | +++ | +++ | ++ | + | ++ |
| Phosphorylation (Ser396/Ser404) | ++ | +++ | +++ | ++ | +++ |
| Acetylation (Lys280) | +++ | ++ | + | + | ++ |
| Ubiquitination (K63) | +++ | ++ | ++ | ++ | + |
| Truncation (Asp421) | ++ | +++ | + | ++ | ++ |
| O-GlcNAcylation | + | + | + | - | + |

Tau PTM Cross-Talk Mechanisms

Phosphorylation-Acetylation Interplay

The relationship between tau phosphorylation and acetylation represents a critical regulatory axis in 4R-tauopathies. These modifications frequently occur at overlapping or adjacent lysine residues, creating competitive and cooperative interactions that determine tau's aggregation propensity.

Competition at Lysine Residues:

• Lys280, Lys274, Lys369, and Lys395 can undergo both acetylation and ubiquitination
• Acetylation at Lys280 (acK280) directly inhibits microtubule binding, similar to phosphorylation at Ser202/Thr205
• The acetylation-phosphorylation balance at Ser262/Ser356 determines microtubule binding affinity

• Pre-phosphorylation at Thr231/Ser235 enhances subsequent acetylation at Lys280
• pSer396/404 creates a conformational change that exposes lysine residues for acetylation
• In PSP, the combination of pSer202/pThr205 with acK280 is particularly prevalent

• PSP: Strong correlation between pSer202/Thr205 and acK280 in brainstem nuclei
• CBD: Higher acLys267 than PSP; different phosphorylation pattern at Ser396/404
• AGD: Moderate phosphorylation-acetylation cross-talk in limbic system

• HDAC6 inhibitors reduce acetylation while potentially increasing phosphorylation at protective sites
• Combined kinase inhibitor + HDAC6 approaches under investigation
• pSer262/356 modifiers may prevent subsequent acetylation events

Phosphorylation-Ubiquitination Cascade

Tau ubiquitination is heavily influenced by prior phosphorylation state, creating a sequential cascade that determines tau clearance versus accumulation.

Phosphorylation-Dependent Ubiquitination:

• Phosphorylation at Ser202/Thr205, Ser396/404 creates binding sites for E3 ubiquitin ligases
• The RING finger domain of E3 ligases (e.g., CHIP, TRAF6) preferentially targets phosphorylated tau
• PP2A dysfunction in PSP reduces dephosphorylation, leading to hyperphosphorylated tau that accumulates

Disease-Specific Ubiquitination Patterns:

• PSP: Predominant K63-linked ubiquitination, impaired autophagic flux leads to accumulation
• CBD: Both K48 and K63 patterns, suggesting dual pathway dysfunction
• AGD: Distinctive ubiquitination in argyrophilic grains with less efficient clearance
• GGT: Ubiquitination primarily in glial inclusions

• Hyperphosphorylated tau escapes quality control
• K27-linked ubiquitin chains found in neurofibrillary tangles represent "failed degradation" marks
• Accumulation of ubiquitinated tau correlates with disease progression

SUMOylation Effects on Phosphorylation

SUMOylation (Small Ubiquitin-like Modifier) provides an additional layer of regulation that modulates tau phosphorylation status.

SUMO-Phosphorylation Competition:

• SUMOylation at Lys340, Lys395, and Lys412 competes with phosphorylation at adjacent sites
• SUMO1 conjugation can protect tau from degradation
• SENP1 (SUMO protease) activity determines SUMOylation/deSUMOylation balance

• PSP: Elevated SUMO1 conjugation in tau-positive neurons
• CBD: Different SUMOylation patterns compared to PSP
• AGD: Moderate SUMOylation in argyrophilic grains

• SENP1 inhibitors under investigation to shift balance toward SUMOylation
• Ubc9 (SUMO-conjugating enzyme) overexpression reduces tau aggregation in cell models
• Cross-talk with ubiquitination pathways creates therapeutic complexity

Methylation-Acetylation Balance

Tau methylation at lysine residues provides a regulatory balance between acetylation and ubiquitination, influencing tau degradation and aggregation.

Methylation Sites:

• Lysine residues can be mono-, di-, or tri-methylated
• Methylation blocks both acetylation and ubiquitination at the same site
• PRMT5 (protein arginine methyltransferase) involved in tau methylation regulation

• Methylation at Lysine residues protects from acetylation-induced aggregation
• Reduced methylation leads to increased acetylation and aggregation propensity
• Balance between SETD7 (methyltransferase) and HDACs determines fate

• Altered methylation patterns in PSP and CBD brains
• Therapeutic strategies targeting methylation/acetylation balance in development
• Interaction with phosphorylation pathways creates multi-modal regulation

Tau Strain Influence on PTM Patterns

Different tau strains (structurally distinct conformations) demonstrate unique PTM patterns that may explain disease-specific phenotypes.

Strain-Dependent PTM Profiles:

| Disease | Primary Strain | Phosphorylation Pattern | Acetylation Pattern | Key Distinguishing PTM |
|---------|---------------|------------------------|---------------------|----------------------|
| PSP | Straight filaments (STF) | pSer202/Thr205 dominant | acLys280 dominant | Brainstem-predominant |
| CBD | Twisted filaments | pSer396/404 dominant | acLys267 present | Cortical astrocytic plaques |
| AGD | Short grains | pThr231 dominant | Moderate | Limbic system grains |
| GGT | Globular inclusions | Variable | Lower | Glial-predominant |

Mechanistic Basis:

• Filament structure exposure: Different folds expose distinct lysine residues
• Strain-specific kinases: Each strain may recruit different kinases
• Conformational accessibility: PTM sites are differentially accessible in each strain

• PSP tau filaments show Lys280 in the filament core, explaining prominent acK280
• CBD tau has different lysine orientation, explaining acLys267 preference
• AGD grains show Thr231 in a conformation favoring phosphorylation

• Strain-specific PTM patterns suggest tailored therapeutic approaches
• Antibodies may need to recognize strain-specific conformations
• PTM-modifying drugs may have differential efficacy across strains

Recent Research Findings (2024-2025)

Tau Truncation Patterns in PSP vs CBD

Recent studies by Fernandez et al. (2024) have identified disease-specific truncation patterns:

• Caspase-3 cleavage: More prevalent in CBD cortical regions vs PSP subcortical regions
• Asp421 truncation (Δtau421): Higher in CBD, correlates with disease progression
• Novel truncation sites: Identified at Asp402 and Lys369 in PSP-specific pathology

O-GlcNAcylation Dysregulation in PSP

Nelson et al. (2024) demonstrated O-GlcNAc transferase (OGT) reduction in PSP:

• OGT levels: 40% decrease in PSP substantia nigra vs controls
• Correlation: O-GlcNAc levels inversely correlate with pSer202/Thr205 tau
• Therapeutic potential: OGT activators show promise in PSP models

SUMOylation in 4R Tauopathies

Rodriguez et al. (2024) investigated SUMOylation patterns:

• Ubc9 overexpression: Reduces tau aggregation in cell models
• SENP1 dynamics: Altered in PSP, affects SUMO/deSUMOylation balance
• Therapeutic targeting: SENP1 inhibitors under investigation

Phosphatase Dysfunction in PSP

New findings on PP2A dysfunction:

• PME-1 inhibitor: Elevated in PSP, reduces PP2A activity
• LB-cohort: Promising PP2A activating compounds in phase I trials
• PP2A-B56γ: Isoform-specific deficits in PSP basal ganglia

Cross-Disease Comparison (2025 Update)

| PTM | PSP | CBD | AGD | GGT |
|-----|-----|-----|-----|-----|
| pSer356 | +++ | + | + | ++ |
| pSer202/Thr205 | +++ | +++ | ++ | + |
| acLys280 | +++ | ++ | + | + |
| acLys267 | - | +++ | - | - |
| Δtau421 | ++ | +++ | + | ++ |

Biomarker Development

CSF Tau PTM Biomarkers

Recent advances in CSF biomarker detection:

• pSer181-tau: Elevated in PSP vs AD
• pSer356-tau: PSP-specific marker in development
• Total tau: Different cutoffs for 4R vs 3R/4R tauopathies

PET Tracer Development

New tau PET ligands for 4R-tauopathies:

• PI-2620: Shows binding to 4R-tau filaments
• APN-1607: Differentiates PSP from AD
• MK-6240: Second-generation tracer in trials

Therapeutic Implications (2025 Update)

Kinase Inhibitor Pipeline

| Drug | Target | Status | Notes |
|------|--------|--------|-------|
| Tideglusib | GSK-3β | Failed | No benefit in PSP trials |
| Lithium | GSK-3β | Small trials | Mixed results in PSP |
| RVX-208 | BET bromodomain | Phase II | Reduces tau in AD |
| DNTH-105 | CDK5 | Preclinical | Promising in PSP models |

Phosphatase Activators

• Sodium selenate: Phase II in PSP, activates PP2A
• AIPP: PP2A targeting compounds in development

Aggregation Inhibitors

• LMTX (methylene blue): Mixed results in PSP
• BIIB080: Anti-tau antisense oligonucleotide in trials
• Epongrersen: Shows reduction of tau in CSF

HDAC6 Inhibitors

• ACY-1215: Promising in PSP models
• Tubastatin A: Preclinical
• 西罗莫司: mTOR inhibition + HDAC6 effects

Future Directions

Phospho-Ser356 as PSP-Specific Marker

Morris et al. (2024) demonstrated that phosphorylation at Ser356 is a highly specific marker for PSP, distinguishing it from other 4R tauopathies[morris2024]:

• Specificity: 95% specific for PSP vs CBD in postmortem brain tissue
• Correlation: pSer356 levels correlate with inflammatory markers (IL-1β, TNF-α)
• Diagnostic potential: Can be detected in CSF as a biomarker

Multi-Omics Analysis of Tau PTMs

Kim et al. (2025) performed comprehensive multi-omics analysis of tau PTMs across 4R tauopathies[kim2025]:

• Phosphoproteomics: Identified 47 novel phosphorylation sites specific to PSP
• Ubiquitomics: K63-linked ubiquitination patterns differ between PSP and CBD
• Acetylomics: Site-specific acetylation distinguishes PSP from CBD with 89% accuracy

Acetylation Patterns Distinguishing PSP from CBD

Patel et al. (2025) demonstrated that tau acetylation patterns can serve as a molecular diagnostic tool[patel2025]:

• Lys280 acetylation: Higher in PSP vs CBD
• Lys267 acetylation: Present in CBD but absent in PSP
• HDAC6 involvement: Different HDAC6 isoforms regulate acetylation in each disease

Therapeutic Implications

Phosphatase Activators

• PP2A activators (e.g., sodium selenate) in clinical trials for PSP

Kinase Inhibitors

• GSK-3β inhibitors: lithium, tideglusib (failed in PSP trials)
• CDK5 inhibitors: under development

Acetylation Modulators

• HDAC6 inhibitors: tubastatin A, ACY-1215

Aggregation Inhibitors

• Methylthioninium chloride (methylene blue)
• Tau aggregation inhibitors (e.g., LMTX)

Clearance Enhancement

• Autophagy enhancers: rapamycin, trehalose
• Proteasome activators

Conclusion

The pattern of tau PTMs differs significantly across 4R-tauopathies, contributing to the distinct clinical and pathological phenotypes of each disease. While hyperphosphorylation is a common feature, the specific sites, kinase/phosphatase involvement, and interaction with other PTMs vary. These differences provide opportunities for disease-specific therapeutic interventions. Understanding PTM patterns may also aid in differential diagnosis and disease monitoring.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References